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Prolonged seizures are amongst the most common neurological emergencies. Status
epilepticus is a state of continuous seizures that is life-threatening and prompt termination
of status epilepticus is critical to protect the brain from permanent damage. Frontline
treatment comprises parenteral administration of anticonvulsants such as lorazepam
that facilitate γ-amino butyric acid (GABA) transmission. Because status epilepticus can
become refractory to anticonvulsants in a significant proportion of patients, drugs which
act on different neurotransmitter systems may represent potential adjunctive treatments.
P2X receptors are a class of ligand-gated ion channel activated by ATP that contributes
to neuro- and glio-transmission. P2X receptors are expressed by both neurons and glia
in various brain regions, including the hippocampus. Electrophysiology, pharmacology
and genetic studies suggest certain P2X receptors are activated during pathologic brain
activity. Expression of several members of the family including P2X2, P2X4, and P2X7
receptors has been reported to be altered in the hippocampus following status epilepticus.
Recent studies have shown that ligands of the P2X7 receptor can have potent effects
on seizure severity during status epilepticus and mice lacking this receptor display
altered seizures in response to chemoconvulsants. Antagonists of the P2X7 receptor also
modulate neuronal death, microglial responses and neuroinflammatory signaling. Recent
work also found altered neuronal injury and inflammation after status epilepticus in mice
lacking the P2X4 receptor. In summary, members of the P2X receptor family may serve
important roles in the pathophysiology of status epilepticus and represent novel targets
for seizure control and neuroprotection.
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INTRODUCTION
Status epilepticus is a potentially devastating neurological condi-
tion of continuous seizures. Current treatments are often unsuc-
cessful in achieving complete seizure suppression, particularly
when delivered late, so novel targets must be identified. ATP-
gated ion channels—P2X receptors—are an interesting new focus
of status epilepticus research. The pleiotropic effects of P2X
receptor activation, including neuromodulation under conditions
of excessive neuronal firing and indirect effects on excitability
via control of neuroinflammation and gliosis offer a “multi-
targeting” mode of action that may be particularly well suited to
suppressing both the immediate pathologic brain activity and its
downstream consequences. This review summarizes recent work
on P2X receptors in status epilepticus, with particular emphasis
on the P2X7 receptor (P2X7R), and speculates on the potential of
these receptors as future drug targets for seizure control.
STATUS EPILEPTICUS AND LIMITATIONS OF CURRENT
TREATMENT
Status epilepticus is a state of continuous seizures, with an annual
incidence ranging from 10 to 86 per 100,000 individuals (Chen
and Wasterlain, 2006). Status epilepticus is traditionally defined
as seizures lasting 30min or more, but the current operational
definition is clinical or electrographic seizures lasting beyond
5min (Brophy et al., 2012). Status epilepticus represents a neu-
rological emergency that is associated with profound morbidity
and mortality. In humans and animal models, status epilep-
ticus results in selective neuronal loss and gliosis, particularly
within the hippocampus, as well as cognitive deficits and last-
ing hyper-excitability (Lowenstein, 2005; Chen and Wasterlain,
2006). Status epilepticus may result from metabolic disturbances,
infection, drug toxicity or withdrawal, and non-compliance with
the taking of anti-epileptic drugs (AEDs) (Brophy et al., 2012).
Identifying the underlying cause of status epilepticus and treat-
ing it appropriately is paramount to alleviating the condition
(Shorvon, 2011).
Pharmacological treatment of status epilepticus has been
reviewed elsewhere (Lowenstein, 2005; Chen and Wasterlain,
2006) and new guidelines were recently published (Brophy
et al., 2012). Initial therapy is to provide parenteral benzodi-
azepines such as lorazepam. Where benzodiazepines fail to con-
trol seizures, second-line therapy is usually with certain AEDs,
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including phenytoin. If both groups of drug fail and status epilep-
ticus has become refractory, treatment options include ongoing
intravenous combinations of the above or alternative treatments
including hypothermia (Brophy et al., 2012). Recent work sup-
ports the use of the N-methyl-D-aspartate (NMDA) receptor
antagonist ketamine for refractory status epilepticus (Synowiec
et al., 2013).
ANIMAL MODELS OF STATUS EPILEPTICUS
Animal models of status epilepticus have been critical for under-
standing the pathophysiology and treatment of status epilepti-
cus. During status epilepticus there is a failure of the normal
mechanisms for seizure termination, such as build-up of the
anticonvulsant adenosine, acidosis or ion channel block. Other
changes also accompany status epilepticus, including internal-
ization of receptors for the inhibitory neurotransmitter γ-amino
butyric acid (GABA) and externalization of receptors for the exci-
tatory neurotransmitter glutamate (Wasterlain and Chen, 2006;
Loscher, 2009). This is thought to underlie the development of
benzodiazepine resistance which is common in status epilepti-
cus. Optimal therapy is still lacking and there remains a need to
identify other targets.
The most common animal models of status epilepticus use a
chemoconvulsant or neurotoxin which is systemically adminis-
tered or injected directly into the brain. Status epilepticus can
also be triggered via electrical stimulation of the brain (e.g.,
perforant pathway, amygdala). Each has advantages and dis-
advantages, which have been reviewed elsewhere (Sperk, 1994;
Loscher, 2002; Curia et al., 2008). To date, only the pilocarpine
and kainic acid models have been used to investigate P2X modu-
lation in vivo. Pilocarpine is a cholinergic agonist which produces
status epilepticus and a pattern of hippocampal damage similar to
that observed in epilepsy patients with mesial temporal sclerosis.
However, induction of status epilepticus by pilocarpine appears
to be secondary to peripheral immune responses and opening
of the blood-brain barrier and the model is associated with high
mortality, inter-animal variability in hippocampal pathology, and
neuronal injury caused by ischemic as well as excitotoxic mecha-
nisms (Fabene et al., 2007; Marchi et al., 2009). While the use of
systemic kainic acid is also associated with variable hippocam-
pal pathology, triggering status epilepticus using an intracerebral
(e.g., intra-amygdala) injection of kainic acid produces a highly
consistent focal and unilateral hippocampal lesion, with minimal
mortality and reliable onset of spontaneous seizures (Li et al.,
2008; Mouri et al., 2008; Liu et al., 2013). Such differences are
important in critical evaluation of some of the conflicting findings
with P2X ligands and genetically-modified mice.
ATP-GATED RECEPTORS; POTENTIAL TARGETS FOR SEIZURE
CONTROL?
ATP acts as a neurotransmitter/co-transmitter in the CNS
where it has important neuromodulatory and trophic effects
(Burnstock, 2008). ATP is released from neurons and glia in
response to neuronal activity via exocytosis as well as through
alternative routes, including hemichannels and other mecha-
nisms (Lazarowski et al., 2003; Dale and Frenguelli, 2009). ATP
can also accumulate because of release from damaged cells.
Convulsive activity produces an overall reduction in brain ATP
levels but intense activation of neuronal pathways also triggers
ATP release (Dale and Frenguelli, 2009). Once released, ATP acts
on ionotropic P2X and metabotropic P2Y receptors, and pro-
duces a mixture of excitatory and inhibitory effects [for review,
see Burnstock (2007); Abbracchio et al. (2009)]. The other major
class of purinoceptor, P1 receptors, is activated by adenosine.
Adenosine is a potent anticonvulsant, and its important contri-
bution to seizure control has recently been reviewed (Boison,
2013a,b).
P2X receptors are all ATP-gated ion channels, usually com-
posed of heterotrimers of individual subunits encoded by seven
different genes (P2rx1-7) that gate fast depolarizing sodium
(Na+) and calcium (Ca2+) entry. A number of additional proper-
ties are attributed to P2X receptors. Extended activation of certain
P2X receptors leads to the formation of a large pore with perme-
ability to small molecules. This is best understood for the P2X7R,
in which the response has been linked to a direct cytolytic effect,
but other members of the P2X family may also form such chan-
nels (Surprenant et al., 1996; Di Virgilio et al., 1998; Virginio et al.,
1999). The pore is not necessarily cytolytic, however, and there is
controversy over whether the pore is instead formed by adjacent
pannexin-1 channels (Duan et al., 2003; Pelegrin and Surprenant,
2006; Iglesias et al., 2008). The P2X7R has a number of other
distinct characteristics. There is a large intracellular domain that
enables it to directly interact with downstream pathways, includ-
ing structural proteins (Kim et al., 2001). The receptor generally
does not form heterotrimers and is found as a homotrimer,
although recent work suggests it can interact with P2X4R in some
cells (Craigie et al., 2013). The P2X7R also has low affinity for
ATP, requiringmM levels for activation (Gever et al., 2006; Skaper
et al., 2010). The implication is that the P2X7R is not activated
under physiological conditions. The necessary conditions to gen-
erate sufficient extracellular ATP to activate P2X7R activation
might include after cell lysis (e.g., neuronal necrosis due to exci-
totoxicity) or pathologic brain activity such as during prolonged
or repeated brief seizures. Another feature of the P2X7R is that
repeated agonist application under certain conditions results in
sensitization and increased inward currents (Chessell et al., 1998;
North and Surprenant, 2000; Armstrong et al., 2002).
Distribution of the P2X receptors has been previously
reviewed, although characterization of their exact subunit com-
position in different tissues and cells is not yet complete
(Norenberg and Illes, 2000; North and Surprenant, 2000; Gever
et al., 2006). P2X receptors are found on neurons, where they may
localize to both pre- and post-synaptic sites, and on non-neuronal
cell types. The main subtypes expressed in the brain, includ-
ing neurons in the hippocampus, are P2X2, 4 and 6 although
P2X1, 3 and 5 receptor transcript and/or immunoreactivity has
also been reported in the hippocampus (Papp et al., 2004; Dona
et al., 2009; Engel et al., 2012a; Ulmann et al., 2013). The P2X7R
was originally cloned from rat brain but considerable contro-
versy has surrounded the exact localization in the brain. Early
studies reported only microglial expression of the P2X7R in the
adult brain (Collo et al., 1997). A number of groups have since
reported P2X7R expression in neurons, including in the hip-
pocampus (Deuchars et al., 2001; Armstrong et al., 2002; Dona
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et al., 2009; Engel et al., 2012a). However, the specificity of the
antibodies used in those studies was questioned by the finding of
widespread immunostaining with different antibodies in P2X7R
knockout mice (Sim et al., 2004). Although that study concluded
that the P2X7R was not expressed at appreciable levels in neu-
rons of the hippocampus, other studies have identified the mRNA
for P2X7R in neurons in the rodent hippocampus (Yu et al.,
2008). New evidence for constitutive expression of the P2X7R
in hippocampal neurons has come from studies of mice express-
ing enhanced green fluorescent protein (EGFP) under the control
of the P2X7R promoter (Engel et al., 2012a,b; Jimenez-Pacheco
et al., 2013). In the normal mouse brain, EGFP is seen in few den-
tate granule neurons and also in certain populations of neurons
in the neocortex (Engel et al., 2012a,b; Jimenez-Pacheco et al.,
2013).
The other major cell type expressing P2X7R in the brain is
microglia (Collo et al., 1997; Rappold et al., 2006; Dona et al.,
2009). Oligodendrocytes also express P2X7R (Matute et al., 2007;
Yu et al., 2008). Although expression of P2X7R has been reported
in cultured astrocytes (Duan et al., 2003), there is limited evidence
for such expression in vivo (Yu et al., 2008; Engel et al., 2012a;
Jimenez-Pacheco et al., 2013). Thus, multiple members of the
P2X receptor family are expressed in brain where they may exert
important modulatory effects on neuro- and glio-transmission
(Khakh, 2001; Abbracchio et al., 2009).
EXPRESSIONAL RESPONSE OF P2X RECEPTORS FOLLOWING
STATUS EPILEPTICUS
Injury to the brain produces widespread changes to the expression
of P2X receptors (Burnstock, 2008). Following status epilep-
ticus, there is a prominent increase in P2X7R immunoreac-
tivity and functional responses in microglia (Rappold et al.,
2006; Avignone et al., 2008). Protein levels of the P2X7R mea-
sured by immunoblotting also increase after status epilepticus
in the hippocampus and neocortex, including in the synapto-
dendritic compartment (Dona et al., 2009; Engel et al., 2012a;
Jimenez-Pacheco et al., 2013). Transcript levels of P2X7R are
increased in hippocampal neurons, particularly granule neurons,
andmicroglia after status epilepticus (Avignone et al., 2008; Engel
et al., 2012a). There has not been convincing in vivo evidence of
changes to P2X7R expression in astrocytes or oligodendrocytes
after status epilepticus (Rappold et al., 2006; Engel et al., 2012a;
Jimenez-Pacheco et al., 2013).
There is less data on expressional responses of other P2X
receptors after status epilepticus. Down-regulation of P2X2R has
been reported after status epilepticus (Engel et al., 2012a) and
P2X2R expression is also decreased in seizure-sensitive gerbils
(Kang et al., 2003). For the P2X4R, studies have reported both up-
and down-regulation in the hippocampus after status epilepticus
(Avignone et al., 2008; Dona et al., 2009). The P2X4R was recently
reported to be up-regulated on hippocampal microglia after sta-
tus epilepticus in rats (Ulmann et al., 2013) but is expressed at
lower levels in the seizure-sensitive gerbil (Kang et al., 2003).
Hippocampal protein levels of P2X1, 3, and 5 receptors, as mea-
sured by immunoblotting, were all unchanged after status epilep-
ticus (Engel et al., 2012a). Thus, status epilepticus produces select
changes to levels of P2X receptors which are likely to result in
altered responsiveness of glia and neurons to ATP signaling in the
brain. A summary of status epilepticus-induced changes to P2X
receptor expression is provided in Table 1.
ROLE OF P2X RECEPTORS IN BRAIN EXCITABILITY
Under physiological circumstances, P2X gated currents at
synapses are thought to be small and not uniformly detected
(North, 2002; Khakh and North, 2006). Intracellular recordings
have estimated the ATP-dependent fast excitatory component
to comprise 5–20% of the total synaptic current in CA1 pyra-
midal cells (Pankratov et al., 2002). The real significance of
P2X receptor-mediated current may be to facilitate Ca2+ entry
into cells. Together with the presynaptic location of certain P2X
receptors, this implicates them in control of neurotransmitter
release (Sperlagh et al., 2007). The distribution of P2X receptors
at synapses—particularly at the periphery of the post-synaptic
density—suggests their contribution becomes more important
under conditions of intense neuronal activity (Khakh and North,
2006).
A number of studies have investigated the effects of P2X
receptor activation or blockade on hippocampal excitability and
there is evidence for both pro- and anti-excitatory consequences.
An excitatory effect of the P2X agonist α, β-meATP was found
in rat hippocampal slices (Ross et al., 1998) and hippocam-
pal slices from seizure-prone mice release more extracellular
ATP when stimulated (Wieraszko and Seyfried, 1989). In con-
trast, blockade of post-synaptic P2X receptors was observed to
facilitate long-term potentiation, suggesting some P2X receptor
functions restrict certain aspects of synaptic plasticity (Pankratov
et al., 2002). P2X2R are present on the presynaptic terminals
of CA3 axons (Schaffer collaterals) that terminate on inhibitory
interneurons in the CA1 subfield and are thought to function
as a physiological brake on excessive neuronal activity (Khakh
and North, 2006). Activation of P2X2R enhances release of
excitatory neurotransmitter onto CA1 interneurons, which in
turn increases release of inhibitory neurotransmitter to reduce
excitatory drive onto CA1 pyramidal neurons (Khakh et al.,
2003). Notably, down-regulation of the P2X2R has been reported
in models of status epilepticus, suggesting loss of this recep-
tor might represent a novel “channelopathy” (Engel et al.,
2012a).
P2X7R also mediate effects on hippocampal excitability.
Stimulation of P2X7R present on the presynaptic terminals of
mossy fibers reduced excitatory field potentials recorded in the
CA3 subfield (Armstrong et al., 2002). These data are consistent
with a model whereby pre-synaptic P2X7R are activated during
high-level neuronal excitability and function to reduce further
release of glutamate frommossy fiber terminals (Armstrong et al.,
2002). The P2X7R effect to decrease transmitter release probabil-
ity at mossy fiber synapses is therefore the opposite of what was
found for pre-synaptically-located P2X2R, which enhanced trans-
mitter release probability, but functionally these actions are syn-
ergistic, to limit over-excitation within the hippocampus. These
results are also consistent with the main effects of ATP being pre-
synaptic, not post-synaptic in the hippocampus (Khakh et al.,
2003). Other recent work in a model of recurrent epileptiform
activity found a small effect of P2X7R antagonists against slow
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Table 1 | P2X receptors in status epilepticus.
Expression in seizure-relevant
brain regions
Expressional response to status
epilepticus
Effect of agonists/antagonists or knockout on status epilepticus,
seizure-induced cell death and inflammation
P2X1 Hippocampusa
Cortexb
Hippocampus
No change (W)c
Up-regulated (qPCR)d
Cortex
not studied
Not studied
P2X2 Hippocampuse,f
Cortexe
Hippocampus
Decreased (W)c
No change (W)g
Cortex
not studied
Not studied
P2X3 Hippocampush
Cortexh
Hippocampus
No change (W)3
Cortex
not studied
Not studied
P2X4 Hippocampusf,i,j
Cortexi,j
Hippocampus
Increased (W, IH)k
No change (W)c,g
Up-regulated (qPCR)d
Cortex
not studied
P2X4 knock-out mice:
Decreased seizure-induced cell death (i.p. KA)k
No effect on seizures (i.p. KA)k
Decreased inflammation and microglia density (i.p. KA)k
No change in IL-1β levels (i.p. KA)k
P2X5 Hippocampusl
Cortexl
Hippocampus:
No change (W)c
Cortex
not studied
Not studied
P2X6 Hippocampusf,i
Cortex i
Not studied Not studied
P2X7 Hippocampusc,m,n
Cortexn,o
Hippocampus:
Increased (W, GFP)c,g
Up-regulated (qPCR)d
Increased (IH)p
Cortex:
Increased (W, GFP)o
Agonists (BzATP):
Increased seizures (i.a. KA)c
No effect on seizures (Pilo)q
Increased microglia activation (Pilo)r
Increase in astrocyte loss (Pilo)s
Increased TNF-α immunoreactivity (Pilo)t
Decreased seizure-induced cell death (Pilo)t
P2X7R knock-out mouse:
Decreased seizures (i.a. KA)c
Increased seizures (Pilo)q
No effect on seizures (i.p. KA and i.p. Pic)q
Antagonists (A-43, A-74, BBG, OxATP, IgG-P2X7):
Decreased seizures (i.a. KA)c,o
Increased seizures (Pilo)q
Decreased seizure-induced cell death (i.a. KA)c
Increased seizure-induced cell death (Pilo)t
Decreased astrocyte loss (Pilo)s
Decreased microglia activation (i.a. KA and Pilo)c,r
Decreased Il-1β levels (i.a. KA)c
A-43, A-438079; A-74, A-740003; BzATP, 2′,3′-O-(4-benzoylbenzoyl)-adenosine 5′-triphosphate; OxATP, oxidised ATP GFP, P2X7R-GFP-reporter mouse; i.a. KA., intra-
amygdala KA; i.p. KA, intra-peritoneal KA; Pilo, Pilocarpine; i.p. Pic, intra-peritoneal Picrotoxin; IgG-P2X7, anti-P2X7 antibodies; Il-1β, interleukin-1beta; qPCR,
quantitative polymerase chain reaction; IH, Immunohistochemistry; TNF-α, Tumor necrosis factor alpha; W, Western blot.
aCavaliere et al., 2007; bLalo et al., 2008; cEngel et al., 2012a; dAvignone et al., 2008; eKanjhan et al., 1999; f Rubio and Soto, 2001; gDona et al., 2009; hSeguela
et al., 1996; iCollo et al., 1996; j Le et al., 1998; kUlmann et al., 2013; lGuo et al., 2008; mArmstrong et al., 2002; nYu et al., 2008; oJimenez-Pacheco et al., 2013;
pRappold et al., 2006; qKim and Kang, 2011; rChoi et al., 2012; sKim et al., 2011a; tKim et al., 2011b.
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field potentials induced by potassium-bicuculline treatment of rat
cortical slices (Klaft et al., 2012).
Overall, the properties of the P2X system—activation under
high levels of neuronal activity—are particularly relevant to
status epilepticus and raise the prospect of a class of recep-
tor that when targeted may influence pathologic brain activ-
ity while leaving normal neurotransmission largely unaffected.
Nevertheless, until very recently, no study had directly inves-
tigated the effect of ligands acting at P2X receptors on status
epilepticus.
In vivo STUDIES WITH P2X7R LIGANDS IN STATUS
EPILEPTICUS
There has been significant interest in P2X7R ligands as therapeu-
tics for neurological conditions (Skaper et al., 2010). The leading
clinical application of P2X7R receptor antagonists is for treatment
of neuropathic pain but there are indications in acute neurologic
injuries. For example, P2X7R antagonists have been reported to
reduce injury or inflammation following intracerebral hemor-
rhage (Chen et al., 2013) and global ischemia (Yu et al., 2013). In
focal cerebral ischemia, protective effects were reported in some
studies (Melani et al., 2006; Arbeloa et al., 2012) but not others
(Le Feuvre et al., 2003). Also of interest, P2X7R agonists have
been shown to trigger a protective state, a form of “chemical
preconditioning,” that rendered cardiac tissue resistant to subse-
quent ischemia (Vessey et al., 2011). Protective effects have also
been reported for P2X7R antagonists in models of neurodegen-
eration, including Huntington’s disease (Diaz-Hernandez et al.,
2009), Parkinson’s disease (Marcellino et al., 2010), amyotrophic
lateral sclerosis (Cervetto et al., 2013) and Alzheimer’s disease
(Diaz-Hernandez et al., 2012; Murphy et al., 2012).
P2X7R antagonists have been reported to produce potent
anticonvulsant effects in some, but not all models of status epilep-
ticus (see Table 1). Studies by the authors demonstrated that
a central (intracerebroventricular) injection the P2X7R antago-
nists BBG or A-438079 resulted in as much as a 50% reduction
in electrographic seizures during status epilepticus triggered by
intra-amygdala microinjection of kainic acid in mice (Engel et al.,
2012a; Jimenez-Pacheco et al., 2013). Behavioral convulsions were
also reported to be reduced in mice treated with A-438079 prior
to status epilepticus (Jimenez-Pacheco et al., 2013). Experiments
using the “Pfizer” P2X7R knockout mice (Solle et al., 2001)
supported these pharmacological studies, with seizure severity
reduced compared to wild-type animals. Further complement-
ing these findings, intracerebroventricular injection of a P2X7R
blocking antibody suppressed seizures while BzATP, a P2X7R
agonist, exacerbated seizures in the model (Engel et al., 2012a).
Analysis of the hippocampus and neocortex of mice pre-treated
with P2X7R antagonists found reductions in neuronal death,
microgliosis and interleukin-1β (Engel et al., 2012a; Jimenez-
Pacheco et al., 2013). Treatment of mice with P2X7R antagonists
20min after triggering status epilepticus - a more clinically-
relevant scenario—also reduced seizure severity and protected the
hippocampus (Engel et al., 2012a). Finally, injection of A-438079
1 h after status epilepticus began, at a time when sensitivity
to lorazepam was reduced, also had modest seizure-suppressive
effects (Engel et al., 2012a). This finding is important since it
supports the possible use of P2X ligands as adjunctive treatments
for status epilepticus alongside frontline drugs such as lorazepam.
These findings add complexity to the pathophysiological func-
tions assigned to the P2X7R in the brain. In vitro data had
supported the P2X7R as a “physiological brake” on overexcitation
(Armstrong et al., 2002) but these in vivo data indicate block-
ing the P2X7R reduces hyper-excitation. It will be important to
establish mechanisms that account for the observed in vivo effects
of P2X7R antagonists against status epilepticus. Direct effects
of P2X7R on neuronal activity may behave differently in vivo
during status epilepticus. For example, the pre-synaptic P2X7R
thought present on mossy fibers facilitating rather than oppos-
ing glutamate release, as demonstrated for P2X2R (Khakh et al.,
2003). Also, perhaps blocking P2X7R on glia (e.g., microglia)
confers anti-excitatory effects that functionally supersede pre-
synaptic effects limiting transmitter release. As always, findings
based mainly on pharmacology require careful consideration of
the specificity of the ligands involved (Anderson and Nedergaard,
2006).
OTHER P2X RECEPTOR LIGANDS IN STATUS EPILEPTICUS
The only other member of the P2X family for which in vivo
data exist in a model of status epilepticus is the P2X4R. Mice
lacking the P2X4R display a reduction in neuronal death after sta-
tus epilepticus, although seizures themselves were not altered in
these mice (Ulmann et al., 2013). Notably, while some inflamma-
tory signaling was also reduced, the induction of interleukin-1β
was not found to be different, supporting other work linking
modulation of this pathway to the P2X7R (see below).
We can speculate that targeting other members of the P2X
family would have seizure-modulating effects in vivo, although
there are fewer ligands selective for the other P2X receptors. An
obvious candidate would be an agonist of the P2X2R. Activation
of this receptor promotes inhibitory transmission within the hip-
pocampus (Khakh and North, 2006). Delivery of such a ligand
might enhance endogenous mechanisms of seizure suppression.
GLIA-RELATED FUNCTIONS OF THE P2X7R IN STATUS
EPILEPTICUS
The immediacy of the seizure-suppressive effects of P2X7R antag-
onists implies a direct action on neurons, for which there is sup-
porting evidence (Armstrong et al., 2002; Engel et al., 2012a,b).
However, expression and activation of the P2X7R on glia may
have important effects on excitability that influence the patho-
physiology and outcome of status epilepticus. First, P2X7R acti-
vation has been associated with production of cytokines from
microglia (Ferrari et al., 1996; Chakfe et al., 2002). In partic-
ular, activation of the P2X7R leads to processing and release
of interleukin-1β, which is a potent pro-convulsive molecule
implicated as a target for seizure control (Vezzani et al., 2010).
Activated microglia also exacerbated excitotoxicity in hippocam-
pal cultures, an effect shown to be P2X7R-dependent (Bernardino
et al., 2008). Thus, targeting P2X7R effects on microglia may
reduce post-status epilepticus inflammation and susceptibility to
excitotoxicity.
P2X7R have been implicated in certain trophic functions,
including the activation and proliferation of microglia. This
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serves both restorative and pathologic functions after status
epilepticus, contributing to tissue repair but also releasing
pro-inflammatory mediators which may contribute to hyper-
excitability (Devinsky et al., 2013). Increased P2X7R expression
and receptor activation was found to transform resting microglia
to an activated state (Monif et al., 2009). Activation of the pore-
forming function of the P2X7R was also found to be required
for microglial proliferation (Monif et al., 2009). Consistent with
this model, blockade of P2X7R reduces microglia activation after
status epilepticus (Kim et al., 2009; Choi et al., 2012; Engel
et al., 2012a). Targeting the pore-forming functions of the P2X7R
may therefore be a novel approach to limit microglia responses
following status epilepticus.
Astrocytes represent another non-excitable cell involved in
mediating the effects of ATP. There is in vitro evidence that
P2X7R activation on astrocytes triggers glutamate release, per-
haps directly through the channel/pore (Duan et al., 2003).
Such P2X7R-mediated glutamate release from astrocytes may
contribute to astrocyte signaling, promote excitability or even
excitotoxicity. P2X7R activation on astrocytes may also serve
a cell-killing function. Injection of rats with the P2X7R ago-
nist BzATP was found to reduce astrocyte numbers after status
epilepticus and P2X7R antagonists prevented astrocyte death
(Kim et al., 2009, 2011a). Thus, secondary effects of P2X7R
ligands will need to be considered as modulation of astrocyte
number or activation has profound effects on excitability in
the brain (Boison, 2008). Oligodendrocytes are also sensitive
to the toxic effects of ATP acting on P2X7R (Matute et al.,
2007).
Finally, it has emerged that the P2X7R may promote axonal
growth and branching in the hippocampus (Diaz-Hernandez
et al., 2008). Studies have also reported that P2X7R antagonists
improved recovery after spinal cord injury (Peng et al., 2009).
Synaptic reorganization is long-recognized following status
epilepticus and has been implicated in establishing recurrent exci-
tatory circuits (e.g., mossy fiber sprouting) that may contribute to
epileptogenesis or chronic epilepsy (Houser et al., 2012). The ben-
efits from targeting the P2X7R could therefore extend well beyond
the initial period of seizure activity. As with effects on astro-
cytes and microglia, these data suggest targeting the P2X7R may
have pleiotropic effects and the timing of manipulations or site of
targeting may be critical to obtain optimal therapeutic benefit.
Figure 1 summarizes the mechanisms of ATP release during
seizures, the receptors upon which ATP may act, expressional
changes, and some of the downstream effects of P2X receptor
modulation relevant to the pathophysiology of status epilepticus.
LIMITATIONS OF TARGETING P2X7 RECEPTORS
While there is significant support for a role for P2X7R in neuronal
injury and/or glial activation, there are also conflicting findings.
Excitotoxic injury has been reported to be unchanged in mice
lacking P2X7R or in response to P2X7R antagonists (Le Feuvre
et al., 2003). Recent work by Frenguelli’s group found a limited
role for P2X receptors in electrically-evoked seizure-like activity
in rat hippocampal slices, and no effect of P2X7R antagonists on
these events (Lopatar et al., 2011). Similarly, no effects of P2X7R
antagonists on in vitro epileptiform activity were detected in acute
cortical slices from epileptic rats (Klaft et al., 2012). Inter-species
differences could be to blame and have been reported for the
P2X7R (Chessell et al., 1998). Last, Kang’s group reported that
pilocarpine-induced seizures were in fact exacerbated in mice
lacking P2X7R and in wild-type animals treated with P2X7R
antagonists (Kim and Kang, 2011). These data are in sharp con-
trast to the findings with intra-amygdala kainic acid-induced
FIGURE 1 | Potential sites of action of ATP released during status
epilepticus, expressional responses of individual P2X receptors, and
consequences of receptor activation. Cartoon depicts the various different
cell types reported to express P2X receptors and their presumed cellular
locations. ATP is released during sustained neuronal activity and from
damaged neurons to act pre- and post-synaptically on neurons, particularly
targeting pre-synaptic receptors to modulate neurotransmitter release. ATP
may also act on receptors of microglia to promote activation and release of
interleukin-1β, and act on astrocytes and oligodendrocytes to trigger cell
death. Drugs such as A-438079 and BBG have been reported to reduce
seizures and gliosis after status epilepticus. SE, status epilepticus; IL-1β,
interleukin-1β.
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status epilepticus (Engel et al., 2012a; Jimenez-Pacheco et al.,
2013). Although the reasons underlying these contradictory find-
ings are uncertain theymay relate to the specificity and dose of the
ligands used, models or genetic tools. Indeed, the findings may
be peculiar to the pilocarpine model because seizures induced
by kainate or picrotoxin were not exacerbated in mice lacking
P2X7R in that study (Kim and Kang, 2011). Another factor may
be the variable influence of tissue responses affecting the phar-
macological properties of the receptor. The P2X7R is inhibited by
acidosis (North, 2002), which develops during status epilepticus
(Ziemann et al., 2008). Does P2X7R blockade develop regardless
of pharmacological antagonism in some models of status epilep-
ticus? Further studies will be needed to resolve these complicated
issues.
OTHER CONSIDERATIONS IN THE DEVELOPMENT OF P2X
LIGANDS FOR STATUS EPILEPTICUS
New P2X receptor ligands have recently emerged while several of
the known P2X antagonists show potentially suitable drug pro-
files. This includes the P2X7R antagonist A-438079, a relatively
small molecule that crosses the blood-brain barrier following sys-
temic delivery (McGaraughty et al., 2007). A recently developed
P2X7R antagonist is also able to pass the blood brain barrier
(Bhattacharya et al., 2013). More complete reviews on the poten-
tial of P2X receptor ligands as drugs can be found elsewhere
(Burnstock, 2008; North and Jarvis, 2013).
Despite the need for new therapies, there has been disengage-
ment of several of the major pharmaceutical companies from
developing new anticonvulsants and treatments for epilepsy. It
has been suggested that the identification of additional clini-
cal applications (i.e., non-epileptic conditions) would make a
potential anticonvulsant drug candidate significantly more attrac-
tive for development (Bialer and White, 2010). One example is
with the effectiveness of certain AEDs for the treatment of pain.
Notably, a key area of deployment of P2X7R antagonists is for
the treatment of pain conditions (Trang et al., 2012; Alves et al.,
2013).
REMAINING CHALLENGES
There are opportunities for the use of P2X receptor ligands in
the control or prevention of seizures but significant challenges
remain. Foremost, P2X7R antagonists need to be evaluated in
other models because of the conflicting reports between kainic
acid and pilocarpine models. These issues are not unique to sta-
tus epilepticus; conflicting data on the P2X7R have emerged in the
stroke field (Le Feuvre et al., 2003; Melani et al., 2006; Yanagisawa
et al., 2008; Arbeloa et al., 2012). A genetic approach will be
needed to confirm specific drug effects are lost in animals lack-
ing the P2X7R, although such studies are not without problems
(Nicke et al., 2009; Masin et al., 2012).
Assuming P2X7R antagonists display consistent anticonvul-
sive profiles, work will be needed to explore dosing and route
of delivery. Do these drugs suppress seizures when given sys-
temically and are there off-target effects? Increased attention is
needed on assessing the pleiotropic actions of these drugs, and
consideration given to looking for effects on glia and inflamma-
tion, including long after the initial period of status epilepticus.
Are anti-inflammatory effects of P2X7R antagonists countered
by trophic effects that promote gliosis? P2X ligands may have
effects against spontaneous seizures, which would raise their
potential as future AEDs. P2X receptors serve important roles in
neurodevelopment and ligands may also have potential to treat
seizures in the developing brain, a condition currently poorly
served by available treatments (Slaughter et al., 2013). It will also
be important to determine the mechanism(s) controlling P2X
receptor expression after status epilepticus. Indeed, efforts to “res-
cue” the post-status epilepticus decline in P2X2R levels could
promote inhibitory transmission. Last, we lack relevant human
data. Although there is evidence for altered expression of P2X
receptors in human epilepsy (Jimenez-Pacheco et al., 2013), their
expression and function in status epilepticus is unknown.
In summary, there is increasing evidence for a role for ATP
and P2X receptors in seizure states such as status epilepticus and
epilepsy. Certain P2X receptors may represent novel drug targets
for seizure control. Targeting these receptors could provide front-
line or adjunctive seizure suppression during status epilepticus,
as well as influencing post-injury glial function that may help
mitigate outcomes including epileptogenesis.
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